SQUAWK/NEWS
Menu
Live News EQUITY L impact

AZN ALXN1210-TMA-313 Phase 3 clinical trial did not meet the primary endpoint.

AZN ALXN1210-TMA-313 Phase 3 clinical trial did not meet the primary endpoint.

AZN ALXN1210-TMA-313 Phase 3 clinical trial did not meet the primary endpoint.